Pin-point Base Editing Access Program: accepting applications now.
Apply for complimentary services to explore how base editing can advance your genomic medicine program.
Revvity is expanding access to next-generation base editing. Through the Pin-point™ Base Editing Access Program, selected researchers receive complimentary evaluation services to explore how modular, high-precision base editing can advance their programs - without the usual barriers to entry.
This is a unique opportunity to turn your idea into evidence.
Selected projects are designed around the applicant’s specific therapeutic challenge, generating relevant preclinical data to move their program forward.
Why apply:
- Tackle challenging edits: Explore whether the modular base editor could offer an advantage for your therapeutic program.
- Find the right strategy: Evaluate multiple editor configurations to balance efficiency, precision, and program needs.
- Move forward with confidence: Generate the evidence you need to advance your program with the right editing approach.
- Simplify access: One license, one partner, expert support from start to finish.
- De-risk exploration: A low-risk way to evaluate advanced ABE and CBE strategies, including multiplex or combinatorial editing,
using clinically-relevant, modular tools.
What’s included:
- Complimentary Pin-point base editing evaluation services, testing up to four target-specific editing configurations to identify promising approaches for your therapeutic application.
- Direct collaboration with our base editing scientists to design and evaluate a Pin-point editing strategy tailored to your therapeutic challenge.
Who can apply:
- Established or early-stage therapeutic R&D teams.
- Projects focused on genomic medicine applications, including gene correction and engineered cell therapies.
Program timeline:
- Applications open: September 14, 2026
- Applications close: November 13, 2026
- Project selections announced: December 18, 2026
- Project kick-off: Within weeks of project sign-off
How to apply:
Tell us about yourself and your project by submitting the short form – it should only take 5-10 minutes.
Our scientific team will review submissions and contact selected applicants by email.
Questions?
- Email us: hd-baseediting@revvity.com
- Learn more about the technology here.
Disclaimer: The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
Click here for the terms and conditions
Terms and Conditions
- Eligibility & Participation: Participation is open to organizations submitting a proposal for access to Pin-point base editing evaluation services. Submission does not guarantee selection. Applications shall be submitted by the deadline.
- Selection Criteria: Proposals will be evaluated based on scientific merit, feasibility, and alignment with Revvity’s strategic interests. Final selection is at Revvity’s sole discretion. Revvity may contact applicants for further information.
- Campaign Offer: Selected applicants may receive:
- Base editing efficiency and specificity data for up to four (4) target-specific ABE configurations as measured by Sanger sequencing after transfection of synthetic base editing reagents in cultured cells, delivered as a service, and
- With a total estimated market value not exceeding USD $10,000.
- Confidentiality: All proposal submissions will be treated as confidential by Revvity. Revvity will not disclose proposal details to third parties without the applicant’s prior written consent, except as required by law.
- No Obligation: Participation in this program does not create any obligation on Revvity to enter into further collaboration, provide services, or offer commercial terms beyond those described herein.
- Modification & Termination: Revvity reserves the right to modify, suspend, or terminate the campaign at any time without prior notice.
